Clinical development failure
Product candidates must succeed in testing before they can be commercialized.
- Scope
- PUR3100, PUR1900 and other inhaled candidates
- Materiality
- high
Pulmatrix, Inc.
Pulmatrix, Inc. is a U.S.-based biopharmaceutical company focused on developing inhaled therapeutic products using its patented iSPERSE™ dry powder delivery platform. Its pipeline has included product candidates for respiratory diseases and central nervous system disorders, with development centered on improving how drugs are delivered to the lungs.
−64,9 %
−66,1 %
12.55
12.55
| % | |
|---|---|
| iSPERSE™ delivery platform | 0% Engineered dry powder technology used to formulate and deliver inhaled drugs. |
| Respiratory disease candidates | 60% Inhaled product candidates aimed at serious lung diseases such as COPD and ABPA. |
| CNS/migraine candidates | 20% Inhaled candidates intended for central nervous system disorders such as acute migraine. |
| Partnered programs and licensing | 20% Programs advanced with collaborators or monetized through licensing and royalties. |
Pulmatrix does not currently sell approved products; its economic model is centered on partnering with pharmaceutical...
- Pharmaceutical licensing partnersprimary
Companies that may license iSPERSE or co-develop inhaled candidates to access the platform and pipeline.
- Clinical development vendorsprimary
CROs and CMOs that perform trials, formulation work, and manufacturing for the pipeline.
- Future patients and prescriberssecondary
Patients and clinicians in respiratory and migraine markets who would use approved inhaled therapies.
- Strategic acquirerssecondary
Potential buyers of assets or the company seeking to monetize the platform or clinical programs.
Pulmatrix is incorporated in Delaware and maintains a mailing address in Framingham, Massachusetts, while operating as...
- •Headquartered in the United States, incorporated in Delaware
- •Virtual company with no owned or leased physical office space
- •Framingham, Massachusetts mailing address and operating base
- •Partnered development outside the United States through collaborators
- •Future commercialization may depend on U.S. and ex-U.S. approvals
Pulmatrix’s strategy is to monetize iSPERSE and its clinical assets through partnerships, licensing, asset sales, or...
01
Monetize the iSPERSE platformshort-term
The platform is the core proprietary asset and the main source of potential value creation.
02
Preserve development optionalitymedium-term
Clinical candidates may still have value if funding or partner support becomes available.
03
Pursue strategic alternativesshort-term
A transaction could provide a path to realize value from the company or its assets.
Pulmatrix faces the typical risks of an early-stage biopharmaceutical company: clinical failure, regulatory delay,...
Regulatory approval risk
The company cannot market products without FDA or foreign approvals.
- Scope
- Respiratory and migraine programs
- Materiality
- high
Third-party execution risk
Clinical trials and manufacturing are outsourced to CROs and CMOs.
- Scope
- Clinical development and supply chain
- Materiality
- high
Financing risk
The company expects to need additional capital to continue operations.
- Scope
- R&D and G&A funding
- Materiality
- high
Transaction and monetization risk
Value realization depends on successful partnering, merger, or asset sale.
- Scope
- Strategic alternatives and merger process
- Materiality
- high
Cybersecurity and data protection risk
Clinical, supplier, and employee data could be disrupted or compromised.
- Scope
- IT systems and third-party interfaces
- Materiality
- medium
Collaboration revenue recognition
Can create lumpy revenue tied to milestones or wind-down activities
R&D expense recognition
Drives operating loss profile and comparability across periods
Impairment and disposal accounting
Could materially affect reported results in transaction periods
Net operating loss carryforwards
Affects deferred tax asset realizability
Pulmonx Corp
LUNG · Surgical & Medical Instruments & Apparatus
Pulmonx Corp is a U.S.-based medical device company focused on minimally invasive treatments for severe emphysema and other advanced chronic obstructive pulmonary disease (COPD) patients.
Ispire Technology Inc.
ISPR · Cigarettes
Theravance Biopharma, Inc.
TBPH · Pharmaceutical Preparations
Theravance Biopharma is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for respiratory and other specialty indications.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD.
Incannex Healthcare Inc.
IXHL · Pharmaceutical Preparations
: 29/04/2026